GH Research (NASDAQ:GHRS) Shares Down 4%

GH Research PLC (NASDAQ:GHRS) fell 4% on Monday . The company traded as low as $10.99 and last traded at $11.02. 26,625 shares traded hands during mid-day trading, a decline of 70% from the average session volume of 88,128 shares. The stock had previously closed at $11.48.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on GHRS. Canaccord Genuity Group boosted their price objective on shares of GH Research from $30.00 to $31.00 and gave the stock a “buy” rating in a report on Monday, May 6th. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of GH Research in a research note on Wednesday, July 31st.

GH Research Trading Down 3.8 %

The firm has a market capitalization of $574.39 million, a PE ratio of -17.81 and a beta of 0.86. The business’s 50 day simple moving average is $11.48 and its two-hundred day simple moving average is $11.08.

Institutional Investors Weigh In On GH Research

Several hedge funds and other institutional investors have recently modified their holdings of GHRS. AdvisorShares Investments LLC increased its stake in shares of GH Research by 4.3% in the 4th quarter. AdvisorShares Investments LLC now owns 48,300 shares of the company’s stock worth $280,000 after purchasing an additional 1,977 shares in the last quarter. Lynx1 Capital Management LP increased its stake in shares of GH Research by 80.1% in the 1st quarter. Lynx1 Capital Management LP now owns 3,310,563 shares of the company’s stock worth $35,291,000 after purchasing an additional 1,471,946 shares in the last quarter. BVF Inc. IL increased its stake in shares of GH Research by 12.1% in the 4th quarter. BVF Inc. IL now owns 10,400,158 shares of the company’s stock worth $60,321,000 after purchasing an additional 1,125,000 shares in the last quarter. Finally, RA Capital Management L.P. increased its stake in shares of GH Research by 11.9% in the 1st quarter. RA Capital Management L.P. now owns 6,251,714 shares of the company’s stock worth $66,643,000 after purchasing an additional 664,381 shares in the last quarter. 56.90% of the stock is currently owned by hedge funds and other institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).